Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 15,009 shares of the business's stock in a transaction that occurred on Tuesday, April 9th. The shares were purchased at an average price of $3.28 per share, with a total value of $49,229.52. Following the completion of the acquisition, the director now owns 838,037 shares of the company's stock, valued at approximately $2,748,761.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Anixa Biosciences Price Performance
NASDAQ ANIX opened at $3.20 on Thursday. Anixa Biosciences, Inc. has a fifty-two week low of $2.75 and a fifty-two week high of $6.45. The stock's 50-day moving average is $3.65 and its two-hundred day moving average is $3.64. The firm has a market cap of $102.08 million, a P/E ratio of -9.41 and a beta of 0.84.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Tuesday, March 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). On average, equities analysts expect that Anixa Biosciences, Inc. will post -0.44 EPS for the current year.
Analysts Set New Price Targets
POTUS in ‘25 Not Biden/Trump, But
From The Freeport Society | Ad
And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.
Click here now to see my urgent election warning.
Separately, HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Anixa Biosciences in a report on Thursday, March 21st.
Check Out Our Latest Stock Report on Anixa Biosciences
Hedge Funds Weigh In On Anixa Biosciences
Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in Anixa Biosciences during the fourth quarter valued at about $43,000. US Bancorp DE grew its position in shares of Anixa Biosciences by 3,312.3% in the first quarter. US Bancorp DE now owns 13,649 shares of the company's stock valued at $37,000 after purchasing an additional 13,249 shares during the last quarter. Dakota Wealth Management acquired a new stake in shares of Anixa Biosciences in the third quarter valued at about $49,000. Tower Research Capital LLC TRC grew its position in shares of Anixa Biosciences by 397.7% in the third quarter. Tower Research Capital LLC TRC now owns 15,763 shares of the company's stock valued at $52,000 after purchasing an additional 12,596 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Anixa Biosciences in the third quarter valued at about $80,000. 29.13% of the stock is currently owned by institutional investors.
Anixa Biosciences Company Profile
(
Get Free Report)
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
